You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
AbbVie researchers validated and extended a previous study to find different types of genetic evidence have varying influences on approval prospects.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
The firm is reassuring participants that their data is secure following media coverage highlighting GMI's position as a fully-owned subsidiary of WuXi NextCode.
AL.com reports Howard Jacob is leaving the HudsonAlpha Institute for Biotechnology after three years there.
Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.
The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.